Hartford Financial Management Inc. Sells 1,780 Shares of CVS Health Co. (NYSE:CVS)

Hartford Financial Management Inc. decreased its holdings in shares of CVS Health Co. (NYSE:CVS) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,817 shares of the pharmacy operator’s stock after selling 1,780 shares during the period. Hartford Financial Management Inc.’s holdings in CVS Health were worth $1,473,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in CVS. Mediolanum International Funds Ltd boosted its holdings in CVS Health by 75.2% in the fourth quarter. Mediolanum International Funds Ltd now owns 23,111 shares of the pharmacy operator’s stock worth $1,013,000 after acquiring an additional 9,917 shares in the last quarter. SOL Capital Management CO boosted its stake in CVS Health by 12.2% in the 4th quarter. SOL Capital Management CO now owns 79,790 shares of the pharmacy operator’s stock worth $3,582,000 after purchasing an additional 8,648 shares in the last quarter. Crews Bank & Trust purchased a new stake in CVS Health during the 4th quarter valued at about $369,000. Swedbank AB raised its holdings in CVS Health by 1.2% in the fourth quarter. Swedbank AB now owns 1,405,812 shares of the pharmacy operator’s stock worth $63,107,000 after buying an additional 16,923 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in shares of CVS Health by 20.1% in the fourth quarter. Hantz Financial Services Inc. now owns 2,416 shares of the pharmacy operator’s stock worth $108,000 after buying an additional 404 shares in the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Performance

CVS opened at $56.84 on Friday. The stock has a market capitalization of $71.53 billion, a price-to-earnings ratio of 14.43, a PEG ratio of 0.62 and a beta of 0.59. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. The company has a fifty day moving average of $51.28 and a 200 day moving average of $56.17.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.01. The company had revenue of $95.43 billion for the quarter, compared to the consensus estimate of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.21 earnings per share. As a group, sell-side analysts forecast that CVS Health Co. will post 5.18 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Thursday, January 23rd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.68%. The ex-dividend date of this dividend is Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Analyst Upgrades and Downgrades

CVS has been the subject of a number of recent analyst reports. Wells Fargo & Company upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $60.00 to $66.00 in a report on Monday, November 18th. Barclays lowered their price target on CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. TD Cowen lifted their price objective on CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, November 25th. StockNews.com downgraded shares of CVS Health from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Finally, UBS Group lifted their target price on shares of CVS Health from $60.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $68.12.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.